Tolebrutinib MS Analysis: Evaluating Economic I...

By João L. Carapinha

June 2, 2025

The Institute for Clinical and Economic Review (ICER) has published an evidence report evaluating tolebrutinib for non-relapsing secondary progressive multiple sclerosis (nrSPMS). The clinical trial data from the Phase III HER...
NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment...
Alzheimer’s Blood Test Diagnostics: FDA Clears First Blood Test for Ear...
EU Establishes Expert Panel for Orphan Paediatric Devices
High Orphan Drug Prices Persist Despite Market Exclusivity Expiration
Navigating EU AI Act Healthcare Compliance: Proactive Steps for Ethical AI In...
Biosimilars Price Competition: Impact on U.S. Pharmaceutical Pricing and Mark...
EMA AI Tool Qualification: How the AIM-NASH Approval Sets a Roadmap for Medic...
EFPIA Advocates for Stronger Life Sciences in EU Multiannual Financial Framework
VIETNARMS Trial Unveils Innovative Hepatitis C Treatment Options
Revolutionizing Hepatitis C Treatment: The Transformative Role of Direct-Acti...
Hepatitis C Investment Impact: Maximizing Health and Economic Returns in China
First At-Home HPV Testing Approval: FDA Clears Teal Wand